{
    "clinical_study": {
        "@rank": "40289", 
        "acronym": "DROPS-2", 
        "arm_group": [
            {
                "arm_group_label": "R348 Ophthalmic Solution, 0.2%", 
                "arm_group_type": "Active Comparator", 
                "description": "R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day"
            }, 
            {
                "arm_group_label": "R348 Ophthalmic Solution, 0.5%", 
                "arm_group_type": "Active Comparator", 
                "description": "R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Ophthalmic Solution 2 drops per eye twice a day"
            }
        ], 
        "brief_summary": {
            "textblock": "-  To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to\n           subjects evaluated by objective and subjective measures.\n\n        -  To investigate the safety and tolerability of R348 Ophthalmic Solutions administered\n           for 12 weeks to subjects."
        }, 
        "brief_title": "To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Chronic Ocular Graft Versus Host Disease (DROPS-2)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Keratoconjunctivitis Sicca in Patients With Chronic Graft-versus-host Disease", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes", 
                "Graft vs Host Disease", 
                "Keratoconjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Received an Allogeneic hematologic stem cell transplantation at least 3 months prior.\n\n          -  Subjects with post Allogeneic hematologic stem cell transplantation  onset or\n             worsening of dry eye symptoms for at least 1 month prior.\n\n          -  Use of over-the-counter and/or prescription eye drops for dry eye symptoms within 1\n             month.\n\n          -  Corneal fluorescein staining score of \u2265 2 in 1 region and \u2265 1 in at least 1 other\n             region.\n\n          -  Total lissamine green conjunctival staining score (according to a modified National\n             Eye Institute grading system) of \u2265 2.\n\n        Exclusion Criteria:\n\n          -  Clinically unstable Graft versus Host Disease (requiring a change in\n             immunosuppressive regimen), medical condition, or laboratory abnormality\n\n          -  Used topical ophthalmic cyclosporine within 45 days.\n\n          -  Used any topical ophthalmic steroid within 2 weeks.\n\n          -  Used autologous serum eye drops within 2 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040623", 
            "org_study_id": "C-932348-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "R348 Ophthalmic Solution, 0.2%", 
                "intervention_name": "R348 Ophthalmic Solution, 0.2%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "R348 Ophthalmic Solution, 0.5%", 
                "intervention_name": "R348 Ophthalmic Solution, 0.5%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo Ophthalmic Solution", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Graft versus Host Disease", 
            "Keratoconjunctivitis Sicca"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Victor Perez, MD", 
                    "phone": "305-326-6302"
                }, 
                "facility": {
                    "address": {
                        "city": "Plantation", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33324"
                    }, 
                    "name": "U. Miami - Bascom Palmer Eye Institute"
                }, 
                "investigator": {
                    "last_name": "Victor Perez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Reza Dana, MD", 
                    "phone": "617-573-4331"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts Eye and Ear Infirmary"
                }, 
                "investigator": {
                    "last_name": "Reza Dana, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change of total Corneal fluorescein staining score", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040623"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Rigel Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigel Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}